TABLE 2.
Clinical and biological data for mothers and newborns of the 20 GBS casesa
| Result group | Data for mothers (N [%]) |
Data for newborns (N [%]) |
|||||
|---|---|---|---|---|---|---|---|
| GBS vaginal carriageb | Antibiotic prophylaxisc | Fever during labor | Vaginal delivery | CRP of >10 μg/mld | Neonatology care unite | GBS materno-fetal infection | |
| Negative | 8 (40) | 12 (60) | 18 (90) | 3 (15) | 13 (65) | 14 (70) | 15 (75) |
| Positive | 11 (55) | 8 (40) | 2 (10) | 17 (85) | 5 (25) | 6 (30) | 5 (25) |
| Not done | 1 (5) | 0 | 0 | 0 | 2 (10) | 0 | 0 |
a
Cases were positive by standard culture and/or Xpert GBS assay for GBS in gastric fluid.
b
Based on antenatal GBS screening of pregnant women at 35 to 37 weeks of gestation.
c
An intrapartum amoxicillin dose of 2 g was delivered.
d
A CRP value less than 10 μg/ml was considered negative for infection. The five newborns with GBS infection had CRP values ranging from 18 to 90 μg/ml.
e
Newborns with severe clinical conditions were hospitalized in the neonatology care unit.